These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 35938615

  • 21. Remyelinating strategies in multiple sclerosis.
    Luessi F, Kuhlmann T, Zipp F.
    Expert Rev Neurother; 2014 Nov; 14(11):1315-34. PubMed ID: 25331418
    [Abstract] [Full Text] [Related]

  • 22. The adult oligodendrocyte can participate in remyelination.
    Duncan ID, Radcliff AB, Heidari M, Kidd G, August BK, Wierenga LA.
    Proc Natl Acad Sci U S A; 2018 Dec 11; 115(50):E11807-E11816. PubMed ID: 30487224
    [Abstract] [Full Text] [Related]

  • 23. Axonal mitochondria adjust in size depending on g-ratio of surrounding myelin during homeostasis and advanced remyelination.
    Ineichen BV, Zhu K, Carlström KE.
    J Neurosci Res; 2021 Mar 11; 99(3):793-805. PubMed ID: 33368634
    [Abstract] [Full Text] [Related]

  • 24. Chronic Demyelination and Axonal Degeneration in Multiple Sclerosis: Pathogenesis and Therapeutic Implications.
    Simkins TJ, Duncan GJ, Bourdette D.
    Curr Neurol Neurosci Rep; 2021 Apr 09; 21(6):26. PubMed ID: 33835275
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Alterations of Oligodendrocyte and Myelin Energy Metabolism in Multiple Sclerosis.
    López-Muguruza E, Matute C.
    Int J Mol Sci; 2023 Aug 18; 24(16):. PubMed ID: 37629092
    [Abstract] [Full Text] [Related]

  • 27. Dynamics of oligodendrocyte generation in multiple sclerosis.
    Yeung MSY, Djelloul M, Steiner E, Bernard S, Salehpour M, Possnert G, Brundin L, Frisén J.
    Nature; 2019 Feb 18; 566(7745):538-542. PubMed ID: 30675058
    [Abstract] [Full Text] [Related]

  • 28. Iron Metabolism in Oligodendrocytes and Astrocytes, Implications for Myelination and Remyelination.
    Cheli VT, Correale J, Paez PM, Pasquini JM.
    ASN Neuro; 2020 Feb 18; 12():1759091420962681. PubMed ID: 32993319
    [Abstract] [Full Text] [Related]

  • 29. Late motor decline after accomplished remyelination: impact for progressive multiple sclerosis.
    Manrique-Hoyos N, Jürgens T, Grønborg M, Kreutzfeldt M, Schedensack M, Kuhlmann T, Schrick C, Brück W, Urlaub H, Simons M, Merkler D.
    Ann Neurol; 2012 Feb 18; 71(2):227-44. PubMed ID: 22367995
    [Abstract] [Full Text] [Related]

  • 30. Structural adaption of axons during de- and remyelination in the Cuprizone mouse model.
    Pfeiffer F, Frommer-Kaestle G, Fallier-Becker P.
    Brain Pathol; 2019 Sep 18; 29(5):675-692. PubMed ID: 31106489
    [Abstract] [Full Text] [Related]

  • 31. Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis.
    Cadenas-Fernández J, Ahumada-Pascual P, Andreu LS, Velasco A.
    Curr Pharm Des; 2021 Oct 05; 27(30):3273-3280. PubMed ID: 33504299
    [Abstract] [Full Text] [Related]

  • 32. Myelin repair stimulated by CNS-selective thyroid hormone action.
    Hartley MD, Banerji T, Tagge IJ, Kirkemo LL, Chaudhary P, Calkins E, Galipeau D, Shokat MD, DeBell MJ, Van Leuven S, Miller H, Marracci G, Pocius E, Banerji T, Ferrara SJ, Meinig JM, Emery B, Bourdette D, Scanlan TS.
    JCI Insight; 2019 Apr 18; 4(8):. PubMed ID: 30996143
    [Abstract] [Full Text] [Related]

  • 33. GD1a Overcomes Inhibition of Myelination by Fibronectin via Activation of Protein Kinase A: Implications for Multiple Sclerosis.
    Qin J, Sikkema AH, van der Bij K, de Jonge JC, Klappe K, Nies V, Jonker JW, Kok JW, Hoekstra D, Baron W.
    J Neurosci; 2017 Oct 11; 37(41):9925-9938. PubMed ID: 28899916
    [Abstract] [Full Text] [Related]

  • 34. Amyloid precursor protein and amyloid precursor-like protein 2 have distinct roles in modulating myelination, demyelination, and remyelination of axons.
    Truong PH, Ciccotosto GD, Merson TD, Spoerri L, Chuei MJ, Ayers M, Xing YL, Emery B, Cappai R.
    Glia; 2019 Mar 11; 67(3):525-538. PubMed ID: 30506868
    [Abstract] [Full Text] [Related]

  • 35. Fibronectin aggregation in multiple sclerosis lesions impairs remyelination.
    Stoffels JM, de Jonge JC, Stancic M, Nomden A, van Strien ME, Ma D, Sisková Z, Maier O, Ffrench-Constant C, Franklin RJ, Hoekstra D, Zhao C, Baron W.
    Brain; 2013 Jan 11; 136(Pt 1):116-31. PubMed ID: 23365094
    [Abstract] [Full Text] [Related]

  • 36. Olig1 function is required for remyelination potential of transplanted neural progenitor cells in a model of viral-induced demyelination.
    Whitman LM, Blanc CA, Schaumburg CS, Rowitch DH, Lane TE.
    Exp Neurol; 2012 May 11; 235(1):380-7. PubMed ID: 22449475
    [Abstract] [Full Text] [Related]

  • 37. Nudging oligodendrocyte intrinsic signaling to remyelinate and repair: Estrogen receptor ligand effects.
    Khalaj AJ, Hasselmann J, Augello C, Moore S, Tiwari-Woodruff SK.
    J Steroid Biochem Mol Biol; 2016 Jun 11; 160():43-52. PubMed ID: 26776441
    [Abstract] [Full Text] [Related]

  • 38. Schwann Cell Remyelination in the Multiple Sclerosis Central Nervous System.
    Ghezzi L, Bollman B, De Feo L, Piccio L, Trapp BD, Schmidt RE, Cross AH.
    Lab Invest; 2023 Jun 11; 103(6):100128. PubMed ID: 36889543
    [Abstract] [Full Text] [Related]

  • 39. Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials.
    Sutiwisesak R, Burns TC, Rodriguez M, Warrington AE.
    Expert Opin Investig Drugs; 2021 Aug 11; 30(8):857-876. PubMed ID: 34126015
    [Abstract] [Full Text] [Related]

  • 40. Lesion stage-dependent causes for impaired remyelination in MS.
    Heß K, Starost L, Kieran NW, Thomas C, Vincenten MCJ, Antel J, Martino G, Huitinga I, Healy L, Kuhlmann T.
    Acta Neuropathol; 2020 Sep 11; 140(3):359-375. PubMed ID: 32710244
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.